

expression systems. Furthermore, the presence or absence of undesired side products can be of high importance.

SUMMARY

The present disclosure refers to bispecific antibodies that particularly consist of two chains although they comprise three antigen binding domains. The antibodies of the present disclosure differ in the spatial orientation of the antigen binding domain from classical antibodies in the IgG format.

The present disclosure provides a bispecific antibody consisting of two fusion polypeptides and comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, wherein

(a) the first fusion polypeptide comprises a first part of a first antigen binding domain capable of specific binding to the first target, a spacer domain, a second part of a first antigen binding domain capable of specific binding to the first target and a first part of an antigen binding domain capable of specific binding to the second target, wherein

- the spacer domain is a polypeptide and comprises at least 25 amino acid residues,
- the first part of the first antigen binding domain capable of specific binding to the first target is fused either directly or via a first peptide linker to the N-terminus of the spacer domain,
- the second part of the first antigen binding domain capable of specific binding to the first target is fused either directly or via a second peptide linker to the C-terminus of the spacer domain, and
- the first part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target or is fused either directly or via a third peptide linker to the N-terminus of the first part of the first antigen binding domain capable of specific binding to the first target, and

(b) the second fusion polypeptide comprising a first part of a second antigen binding domain capable of specific binding to a first target, a spacer domain, a second part of the second antigen binding domain capable of specific binding to a first target and the second part of an antigen binding domain capable of specific binding to a second target, wherein

- the spacer domain is a polypeptide and comprises at least 25 amino acid residues,

- the first part of the second antigen binding domain capable of specific binding to a first target is fused either directly or via a first peptide linker to the N-terminus of the spacer domain,

- the second part of the second antigen binding domain capable of specific binding to a first target is fused either directly or via a second peptide linker to the C-terminus of the spacer domain, and

- the second part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second part of the second antigen binding domain capable of specific binding to a first target or is fused either directly or via a third peptide linker to the N-terminus of the first part of the second antigen binding domain capable of specific binding to a first target,

wherein the first part and the second part of the antigen binding domain capable of specific binding to the second target are associated with each other to form the antigen binding domain capable of specific binding to the second target and wherein the first part and the second part of the first and second antigen binding domain capable of specific binding to the first target are associated with each other to form a circular fusion polypeptide, and

wherein the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise modifications promoting the association of the first and second fusion polypeptide.

In one aspect, the present disclosure provides a bispecific antibody consisting of two fusion polypeptides and comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target comprising

(a) a first fusion polypeptide comprising a first part of a first antigen binding domain capable of specific binding to the first target, a spacer domain, a second part of a first antigen binding domain capable of specific binding to the first target and a first part of an antigen binding domain capable of specific binding to the second target, wherein

- the spacer domain is a polypeptide and comprises at least 25 amino acid residues,

- the first part of the first antigen binding domain capable of specific binding to the first target is fused via a first peptide linker to the N-terminus of the spacer domain,

- the second part of the first antigen binding domain capable of specific binding to the first target is fused via a second peptide linker to the C-terminus of the spacer domain, and

- the first part of an antigen binding domain capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target or is fused via a third peptide linker to the N-terminus of the first part of the first antigen binding domain capable of specific binding to the first target, and

(b) a second fusion polypeptide comprising a first part of a second antigen binding domain capable of specific binding to a first target, a spacer domain, a second part of the second antigen binding domain capable of specific binding to a first target and the second part of an antigen binding domain capable of specific binding to a second target, wherein

- the spacer domain is a polypeptide and comprises at least 25 amino acid residues,

- the first part of the second antigen binding domain capable of specific binding to a first target is fused via a first peptide linker to the N-terminus of the spacer domain,

- the second part of the second antigen binding domain capable of specific binding to a first target is fused via a second peptide linker to the C-terminus of the spacer domain, and

- the second part of an antigen binding domain capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second part of the second antigen binding domain capable of specific binding to a first target or is fused via a third peptide linker to the N-terminus of the first part of the second antigen binding domain capable of specific binding to a first target,

and wherein the first part and the second part of the antigen binding domain capable of specific binding to the second target are associated with each other to form the antigen binding domain capable of specific binding to the second target and wherein the first part and the second part of the first and second antigen binding domain capable of specific binding to the first target are associated with each other to form a circular fusion polypeptide, and

wherein the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise modifications promoting the association of the first and second fusion polypeptide, and wherein the spacer domain of the first fusion polypeptide comprises holes and the spacer domain of the second fusion polypeptide comprises knobs according to the knobs into hole method.

In one example, provided is a bispecific antibody as defined herein before, wherein in the first fusion polypeptide the first part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target and wherein in the second fusion polypeptide the second part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target.

In another example, provided is a bispecific antibody as defined herein before, wherein in the first fusion polypeptide the first part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the N-terminus of the first part of the first antigen binding domain capable of specific binding to the first target and wherein in the second fusion polypeptide the second part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the N-

The present disclosure, in another aspect, provides a pharmaceutical composition comprising the bispecific antibody of the present disclosure and at least one pharmaceutically acceptable excipient.

5 The present disclosure, in another aspect, provides the bispecific antibody of the present disclosure, or the pharmaceutical composition of the present disclosure, for use as a medicament. More particularly, provided is also the bispecific antibody of the disclosure for use in treating cancer or infectious diseases. In another aspect, the present disclosure provides the bispecific antibody of the disclosure or the pharmaceutical composition of the disclosure for use in treating cancer or infectious diseases. In particular, the bispecific antibody of the disclosure for use in
10 treating cancer is provided.

The present disclosure provides the use of bispecific antibody of the present disclosure, or the pharmaceutical composition of the present disclosure, in the manufacture of a medicament for use

- (i) in stimulating T cell response,
- 15 (ii) in supporting survival of activated T cells,
- (iii) in the treatment of infections,
- (iv) in the treatment of cancer,
- (v) in delaying progression of cancer, or
- (vi) in prolonging the survival of a patient suffering from cancer.

20 In another aspect, the present disclosure provides the use of the bispecific antibody of the disclosure or the pharmaceutical composition of the disclosure in the manufacture of a medicament for the treatment of infections or cancer.

The present disclosure also provides a method of treating an individual having cancer or infectious diseases comprising administering to the individual an effective amount of the
25 bispecific antibody of the present disclosure, or the pharmaceutical composition of the present disclosure.

The present disclosure also provides the use of the bispecific antibody of the present disclosure, or the pharmaceutical composition of the present disclosure, in the manufacture of a medicament for up-regulating or prolonging cytotoxic T cell activity. Also provided is a method
30 of up-regulating or prolonging cytotoxic T cell activity in an individual having cancer, comprising administering to the individual an effective amount of the bispecific antibody of the present disclosure, or the pharmaceutical composition of the present disclosure. In some examples in accordance with various aspects of the present disclosure the individual is a mammal, particularly a human.

Claims

1. A bispecific antibody consisting of two fusion polypeptides and comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target comprising

- 5 (a) a first fusion polypeptide comprising a first part of a first antigen binding domain capable of specific binding to the first target, a spacer domain, a second part of a first antigen binding domain capable of specific binding to the first target and a first part of an antigen binding domain capable of specific binding to the second target, wherein
 - 10 - the spacer domain is a polypeptide and comprises at least 25 amino acid residues,
 - the first part of the first antigen binding domain capable of specific binding to the first target is fused via a first peptide linker to the N-terminus of the spacer domain,
 - the second part of the first antigen binding domain capable of specific binding to the first target is fused via a second peptide linker to the C-terminus of the spacer
 - 15 domain, and
 - the first part of an antigen binding domain capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target or is fused via a third peptide linker to the N-terminus of the first part of the first antigen
 - 20 binding domain capable of specific binding to the first target, and
- (b) a second fusion polypeptide comprising a first part of a second antigen binding domain capable of specific binding to a first target, a spacer domain, a second part of the second antigen binding domain capable of specific binding to a first target and the second part of an antigen binding domain capable of specific binding to a second
- 25 target, wherein
 - the spacer domain is a polypeptide and comprises at least 25 amino acid residues,
 - the first part of the second antigen binding domain capable of specific binding to a first target is fused via a first peptide linker to the N-terminus of the spacer domain,
 - the second part of the second antigen binding domain capable of specific binding to a first target is fused via a second peptide linker to the C-terminus of the spacer
 - 30 domain, and
 - the second part of an antigen binding domain capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second part of the second antigen binding domain capable of specific binding to a first target or is

fused via a third peptide linker to the N-terminus of the first part of the second antigen binding domain capable of specific binding to a first target,

and wherein the first part and the second part of the antigen binding domain capable of specific binding to the second target are associated with each other to form the antigen binding domain capable of specific binding to the second target and wherein the first part and the second part of the first and second antigen binding domain capable of specific binding to the first target are associated with each other to form a circular fusion polypeptide, and

wherein the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise modifications promoting the association of the first and second fusion polypeptide, and wherein the spacer domain of the first fusion polypeptide comprises holes and the spacer domain of the second fusion polypeptide comprises knobs according to the knobs into hole method.

2. The bispecific antibody of claim 1, wherein in the first fusion polypeptide the first part of an antigen binding domain capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target and wherein in the second fusion polypeptide the second part of an antigen binding domain capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target.
3. The bispecific antibody of claims 1 or 2, wherein the third peptide linker connecting the first part or the second part of an antigen binding domain capable of specific binding to a second target comprises at least 15 amino acids.
4. The bispecific antibody of any one of claims 1 to 3, wherein the first fusion polypeptide comprises the heavy chain variable domain of the antigen binding domain capable of specific binding to a second target and the second fusion polypeptide comprises the antibody light chain variable domain of the antigen binding domain capable of specific binding to a second target or vice versa.
5. The bispecific antibody of any one of claims 1 to 4, wherein in both the first fusion polypeptide and the second fusion polypeptide the first part of the antigen binding domain capable of specific binding to the first target is an antibody heavy chain Fab fragment and the second part of the antigen binding domain capable of specific binding to the first target is an antibody light chain Fab fragment.

6. The bispecific antibody of any one of claims 1 to 5, wherein the spacer domain comprises an antibody hinge region or a fragment thereof, an antibody CH2 domain, and an antibody CH3 domain or a fragment thereof.
7. The bispecific antibody of any one of claims 1 to 6, wherein the spacer domain comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain.
8. The bispecific antibody of claim 7, wherein the IgG1 Fc domain comprises amino acid substitutions L234A, L235A and P329G (numbering according to Kabat EU index).
9. The bispecific antibody of any one of claims 1 to 8, wherein the antigen binding domain capable of specific binding to a second target is an antigen binding domain capable of specific binding to a tumor associated antigen.
10. The bispecific antibody of any one of claims 1 to 9, wherein the antigen binding domain capable of specific binding to a second target is an antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP).
11. The bispecific antibody of any one of claims 1 to 10, wherein the antigen binding domain capable of specific binding to a second target comprises
 - (a) a heavy chain variable region (V_HFAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a light chain variable region (V_LFAP) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, or
 - (b) a heavy chain variable region (V_HFAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:11, and a light chain variable region (V_LFAP) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:12, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:13, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:14.
12. The bispecific antibody of any one of claims 1 to 11, wherein the antigen binding domain capable of specific binding to a second target comprises
 - (a) a heavy chain variable region (V_HFAP) comprising an amino acid sequence of SEQ ID NO:7, and a light chain variable region (V_LFAP) comprising an amino acid sequence SEQ ID NO:8, or
 - (b) a heavy chain variable region (V_HFAP) comprising an amino acid sequence of SEQ ID

NO:15, and a light chain variable region (V_LFAP) comprising an amino acid sequence of SEQ ID NO:16.

13. The bispecific antibody of any one of claims 1 to 12, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to OX40.

14. The bispecific antibody of any one of claims 1 to 13, wherein the antigen binding domain capable of specific binding to a first target comprises

(a) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:22, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:35, or

(b) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34, or

(c) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:36, or

(d) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:24, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37, or

(e) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:25, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:29, (v) CDR-L2 comprising the amino acid sequence of SEQ ID

- NO:32, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:38, or
(f) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino
acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ
ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:26, and a
5 light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid
sequence of SEQ ID NO:29, (v) CDR-L2 comprising the amino acid sequence of SEQ ID
NO:32, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:38, or
(g) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino
acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ
10 ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:27, and a
light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid
sequence of SEQ ID NO:30, (v) CDR-L2 comprising the amino acid sequence of SEQ ID
NO:33, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:39.
15. The bispecific antibody of any one of claims 1 to 14, wherein the antigen binding domain
15 capable of specific binding to a first target comprises
(a) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID
NO:40 and a light chain variable region (V_LOX40) comprising an amino acid sequence of
SEQ ID NO:41, or
(b) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID
20 NO:42 and a light chain variable region (V_LOX40) comprising an amino acid sequence of
SEQ ID NO:43, or
(c) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID
NO:44 and a light chain variable region (V_LOX40) comprising an amino acid sequence of
SEQ ID NO:45, or
25 (d) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID
NO:46 and a light chain variable region (V_LOX40) comprising an amino acid sequence of
SEQ ID NO:47, or
(e) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID
NO:48 and a light chain variable region (V_LOX40) comprising an amino acid sequence of
30 SEQ ID NO:49, or
(f) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID
NO:50 and a light chain variable region (V_LOX40) comprising an amino acid sequence of
SEQ ID NO:51, or
(g) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID
35 NO:52 and a light chain variable region (V_LOX40) comprising an amino acid sequence of
SEQ ID NO:53.

16. The bispecific antibody of any one of claims 1 to 14, wherein the antigen binding domain capable of specific binding to a first target comprises
(a) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:40, and a light chain variable region (V_LOX40) comprising an amino acid sequence of
5 SEQ ID NO:41.
17. The bispecific antibody of any one of claims 1 to 12, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to 4-1BB.
18. The bispecific antibody of any one of claims 1 to 12 or 17, wherein the antigen binding
10 domain capable of specific binding to a first target comprises a heavy chain variable region (V_H4-1BB) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:135, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:136, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:137, and a light chain variable region (V_L4-1BB) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID
15 NO:138, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:139, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:140.
19. The bispecific antibody of any one of claims 1 to 12 or 17 or 18, wherein the antigen binding domain capable of specific binding to a first target comprises a heavy chain variable region (V_H4-1BB) comprising an amino acid sequence of SEQ ID NO:141, and a light chain
20 variable region (V_L4-1BB) comprising an amino acid sequence of SEQ ID NO:142.
20. The bispecific antibody of any one of claims 1 to 12, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to CD40.
21. The bispecific antibody of any one of claims 1 to 12 or 20, wherein the antigen binding
25 domain capable of specific binding to a first target comprises a heavy chain variable region (V_HCD40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:147, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:148, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:149, and a light chain variable region (V_LCD40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:150,
30 (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:151, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:152.

22. The bispecific antibody of any one of claims 1 to 12 or 20 or 21, wherein the antigen binding domain capable of specific binding to a first target comprises a heavy chain variable region (V_HCD40) comprising an amino acid sequence of SEQ ID NO:153, and a light chain variable region (V_LCD40) comprising an amino acid sequence of SEQ ID NO:154.
- 5 23. The bispecific antibody of any one of claims 1 to 12 or 20 or 21, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to a first target comprises
- 10 (i) a heavy chain variable region (V_HCD40) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169 and SEQ ID NO:170, and a light chain variable region (V_LCD40) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, and SEQ ID NO:174, or
- 15 (ii) a heavy chain variable region (V_HCD40) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179 and SEQ ID NO:180, and a light chain variable region (V_LCD40) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, and SEQ ID NO:184.
24. Isolated nucleic acid encoding the bispecific antibody of any one of claims 1 to 23.
- 20 25. A vector or host cell comprising the nucleic acid of claim 24.
26. A method of producing a bispecific antibody culturing the host cell of claim 25 under conditions suitable for the expression of the bispecific antibody.
27. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to 23 and a pharmaceutically acceptable excipient.
- 25 28. The bispecific antibody of any one of claims 13 to 23 or the pharmaceutical composition of claim 27 for use as medicament.
29. The bispecific antibody of any one of claims 13 to 23 or the pharmaceutical composition of claim 27 for use in treating cancer or infectious diseases.

30. Use of the bispecific antibody of any one of claims 13 to 23 or the pharmaceutical composition of claim 27 in the manufacture of a medicament for the treatment of infections or cancer.
- 5 31. The pharmaceutical composition of claim 27, the bispecific antibody or the pharmaceutical composition for use of claim 28 or 29, or the use of claim 30, further comprising an additional therapeutic agent.
